Table 6.
Immunotherapy-clinical trials.
| Immunotherapeutic Agent | Clinical Trials | Active | Completed | Target |
|---|---|---|---|---|
| Ipilimumab | 6 | 5 | 1 | CTLA-4 |
| Nivolumab | 4 | 4 | 0 | PD-1 |
| Spartalizumab | 1 | 1 | 0 | PD-1 |
| Pembrolizumab | 3 | 2 | 1 | PD-1 |
| PDR001 | 1 | 1 | 0 | PD-1 |
| Avelumab | 2 | 2 | 0 | PD-1 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.